Academic Journal
Q2Blood Research
About Blood Research
Blood Research is a scholarly journal published by Springer. SCImago 2025 lists it in Q2, with an SJR of 0.924 and H-index of 38.
Coverage: 2013-2026. Research categories: Hematology (Q2).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2025-12-02. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Lymphoma Diagnosis and Treatment; Acute Myeloid Leukemia Research; Chronic Lymphocytic Leukemia Research; Chronic Myeloid Leukemia Treatments; Hematopoietic Stem Cell Transplantation; Myeloproliferative Neoplasms: Diagnosis and Treatment.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Diagnostic challenges posed by the wide morphological and immunophenotypic spectrum of plasma cell neoplasms
Shih-Sung Chuang, Chung-Che Chang
2026-12 · DOI: 10.1007/s44313-026-00179-6Sitosterolemia presenting as unexplained cytopenias: hematologic manifestations and genetic spectrum
Navneet Mishra, Nitin Gupta, Naman Bansal, Meena Verma et al.
2026-12 · DOI: 10.1007/s44313-026-00176-9Unveiling the role of circulating monocyte-macrophage polarization state and PD-L1/PD-L2 expression in newly diagnosed pediatric ITP
Asmaa M Zahran, Omnia El-Badawy, Mervat A. M. Youssef, Mena Sameh Yousef Ghattas et al.
2026-12 · DOI: 10.1007/s44313-026-00163-0Telomere length analysis using qPCR in aplastic anemia: prevalence and predictive value for germline mutation status
Sudhanshi Raina, Arihant Jain, Venus Thakur, Anand Balakrishnan et al.
2026-12 · DOI: 10.1007/s44313-026-00182-xFerroptosis-related genes influence AML risk through immune cell–mediated pathways: a Mendelian randomization study with mediation analysis
Qi Meng, Zihao Zhou, Wanchao Zhang
2026-12 · DOI: 10.1007/s44313-026-00166-xExpanding the spectrum of post-HSCT hemolysis: from passenger lymphocyte syndrome to host- and graft-associated alloimmune hemolytic anemia
Dong Wook Jekarl, Jungjun Lee, Yujin Cha, Jay Ho Han et al.
2026-12 · DOI: 10.1007/s44313-026-00173-yHigh-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy
Dong Won Baek
2026-12 · DOI: 10.1007/s44313-026-00175-wCorrection: Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability
Yuichi Horigome, Koichi Ehata, Noriyuki Tadera, Kei Hayama et al.
2026-12 · DOI: 10.1007/s44313-026-00178-7Limited evidence for causal effects of circulating inflammatory cytokines on the risk of selected hematologic malignancies: a two-sample Mendelian randomization study
Huimin Zhang, Lihong Zhang, Dan Zhao, Bing Ma et al.
2026-12 · DOI: 10.1007/s44313-026-00164-zDaratumumab monotherapy for relapsed AL amyloidosis: a single center retrospective analysis
Jun Ho Yi, Sang Eun Yoon, Seok Jin Kim, Darae Kim et al.
2026-12 · DOI: 10.1007/s44313-026-00174-xCRS and ICANS: Early detection and personalized management
Jinchul Kim
2026-12 · DOI: 10.1007/s44313-026-00167-wFLT3-mutated AML: standards of care and ongoing investigation
Ly V. Do, Jessica J. Jorgensen, Kieran D. Sahasrabudhe
2026-12 · DOI: 10.1007/s44313-026-00171-0Cold agglutinin disease: pathophysiology, diagnosis, and the evolving therapeutic landscape
Dae-Ho Choi
2026-12 · DOI: 10.1007/s44313-026-00169-8Association of the PROC rs146922325 variant with venous thrombosis in a Taiwanese population
Chi-Yen Chen, I-Chieh Chen, Guan-Cheng Lin, Tzu-Hung Hsiao et al.
2026-12 · DOI: 10.1007/s44313-026-00168-9Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability
Yuichi Horigome, Koichi Ehata, Noriyuki Tadera, Kei Hayama et al.
2026-12 · DOI: 10.1007/s44313-026-00165-yNeutropenia in adult patients with thalassemia receiving deferiprone: a 10-year experience from a large thalassemia cohort
Ploylarp Lertvipapath, Weerapat Owatanapanich, Waratchaya Uawattanasakul, Smith Kungwankiattichai et al.
2026-12 · DOI: 10.1007/s44313-026-00159-wTargeting CDK7 to overcome hypomethylating agent resistance in acute myeloid leukemia
Bon-Kwan Koo, Eun-Ji Choi, Ju Hyun Moon, Ji Yun Kim et al.
2026-12 · DOI: 10.1007/s44313-026-00162-1Feasibility of therapeutic drug monitoring of asparaginase across multiple formulations in pediatric acute lymphoblastic leukemia
Hyery Kim, Juyeon Yu, Su Hyun Yoon, Sunghan Kang et al.
2026-12 · DOI: 10.1007/s44313-026-00160-3G6PD activity patterns and a stable adjusted male median derived from 16 years of clinical laboratory data
Muhammad Shariq Shaikh, Zeeshan Ansar Ahmed
2026-12 · DOI: 10.1007/s44313-026-00158-xClonal hematopoietic mutations as a predictor of adverse outcomes in cytopenic patients with chronic kidney disease
Suwannaporn Yaophrukchai, Chantana Polprasert, Sirorat Kobbuaklee, Ponlapat Rojnuckarin et al.
2026-12 · DOI: 10.1007/s44313-026-00161-2Reviews
Community Reviews
Version History
October 4, 2026 at 9:01 pm
October 2, 2026